Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study

Sokounthie Ou; Emmanuelle Tancrède-Bohin; Marina Alexandre; Saskia Ingen-Housz-Oro; Marion Castel; Sébastien Debarbieux; Sophie Duvert-Lehembre; Maria Polina Konstantinou; Claire Abasq; Clémence Berthin; Caroline Couzan; Clémence Lepelletier; Lamia Jelti; Julie Bouteiller; Andreea Calugareanu; Marie Véron; Frédéric Caux; Pascal Joly; Bérenger Thomas; Manuelle Viguier; French Study Group on Autoimmune Bullous Skin Diseases

doi:10.1016/j.jaad.2023.08.101

Efficacy and safety of anti-COVID-19 vaccination in patients with autoimmune blistering diseases: A French national study

J Am Acad Dermatol. 2024 Jan;90(1):204-208. doi: 10.1016/j.jaad.2023.08.101. Epub 2023 Sep 26.

Authors

Sokounthie Ou¹, Emmanuelle Tancrède-Bohin², Marina Alexandre³, Saskia Ingen-Housz-Oro⁴, Marion Castel⁵, Sébastien Debarbieux⁶, Sophie Duvert-Lehembre⁷, Maria Polina Konstantinou⁸, Claire Abasq⁹, Clémence Berthin¹⁰, Caroline Couzan¹¹, Clémence Lepelletier², Lamia Jelti⁴, Julie Bouteiller⁵, Andreea Calugareanu¹², Marie Véron¹³, Frédéric Caux³, Pascal Joly⁵, Bérenger Thomas¹⁴, Manuelle Viguier¹⁵; French Study Group on Autoimmune Bullous Skin Diseases

Affiliations

¹ Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France.
² Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
³ Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM UMR1125, Bobigny, France.
⁴ Department of Dermatology, Henri-Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, University Paris Est Créteil, EpidermE, Créteil, France.
⁵ Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and INSERM U1234, Normandie University, Rouen, France.
⁶ Department of Dermatology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France.
⁷ Department of Dermatology, Lille University Hospital, Lille, France; Department of Dermatology, Dunkerque Hospital, Dunkerque, France.
⁸ Department of Dermatology, Larrey Hospital, Toulouse, France.
⁹ Department of Dermatology, Augustin-Morvan Hospital, Brest, France.
¹⁰ Department of Dermatology, Angers Hospital, Angers, France.
¹¹ Department of Dermatology, Saint-Étienne Hospital, Saint-Étienne, France.
¹² Department of Dermatology, Édouard Herriot Hospital, Lyon, France.
¹³ Department of Dermatology, Lille University Hospital, Lille, France.
¹⁴ Department of Epidemiology, Faculty of Medicine, Sorbonne University, Paris, France.
¹⁵ Department of Dermatology, Reims University Hospital, Centre de Référence des Maladies Bulleuses Auto-immunes, MALIBUL and EA7509, IRMAIC, Université Reims-Champagne Ardenne, Reims, France. Electronic address: mviguier@chu-reims.fr.

PMID: 37769901
DOI: 10.1016/j.jaad.2023.08.101

No abstract available

Keywords: COVID-19; SARS-CoV-2; autoimmune bullous disease; efficacy; flare; immunosuppression; infection; safety; vaccination.

MeSH terms

Autoimmune Diseases*
Humans
Patients*
Vaccination / adverse effects